Skip to main content
Study Name | Study Population Focus | Sample Size | Study Domain | Study Design | Data Collection Method | NIH Institute / Center | Center | Has Data Files | |
|---|---|---|---|---|---|---|---|---|---|
| A Longitudinal Study of Digital Biomarkers for Early Detection of Cardiometabolic Risk | Lower Socioeconomic Status (SES) Populations | Serological or Antibody Testing | Clinical Genetic Testing | Interview or Focus Group | NCATS | Demo University 1 | Yes | ||
| AI-Driven Prediction of COVID-19 Clinical Deterioration Using Multimodal Electronic Health Record Data | Dialysis Patients; Adults; Older Adults or Elderly | 25000 | Digital Health Applications; Artificial Intelligence or Machine Learning; Comorbidities | Longitudinal Cohort | Disease Registry; Real-World Data | NIDDK; NLM | AFF-Four | No | |
| COVID-19 Antibody Kinetics and Mucosal Immunity in Individuals with Intellectual and Developmental Disabilities | Adults; Children; Intellectual or Developmental Disabilities | 300 | Immune Responses; Serological or Antibody Testing; Health Behaviors | Observational; Longitudinal Cohort | Antibody or Adaptive Immune Response Testing; Survey; Interview or Focus Group | NICHD; NIAID; NIMHD | AFF-Two | No | |
| COVID-19 Hotspot Identification Using Geospatial Analytics and At-Home Self-Testing Data From Underserved Urban Corridors | Hispanics or Latinos; Essential Workers; Underserved or Vulnerable Populations; Lower Socioeconomic Status (SES) Populations | 3500 | At-Home or Over-the-Counter (OTC) Self-Testing; COVID Hotspots; Digital Health Applications; Geospatial Analysis | Time-Series; Observational | Contact Tracing; Smartphone; Antigen Testing Device | NIEHS; NIBIB; NIMHD | AFF-Three | Yes | |
| COVID-19 Testing and Infection Outcomes Among People Living with HIV on Antiretroviral Therapy | Sexual or Gender Minorities; Hispanics or Latinos; African Americans; People Living with HIV/AIDS | 3200 | Comorbidities; Immune Responses; Diagnostic Testing; Health Behaviors | Observational; Longitudinal Cohort | Antigen Testing Device; Molecular Nucleic Acid or PCR Testing Device; Disease Registry | NIAID; NIMHD | AFF-Four | No | |
| COVID-19 Transmission Dynamics, Testing Strategies, and Mitigation Measures in K-12 School Settings | Children; School Communities | 12000 | COVID in School Settings; Contact Tracing; Screening Testing; Testing Rate or Uptake | Open Cohort; Longitudinal Cohort | Antigen Testing Device; Real-World Data; Survey; Contact Tracing | NIAID; NICHD | AFF-Two | No | |
| Case-Control Analysis of Immune Response Biomarkers and Seroprevalence Among First Responders During COVID-19 Surges | Essential Workers; African Americans; Hispanics or Latinos | 750 | Serological or Antibody Testing; Immune Responses; Seroprevalence | Case-Control | Antibody or Adaptive Immune Response Testing; Biobank Samples | NIAID; NIMHD | AFF-Four | No | |
| Chemosensory Testing and Olfactory Biomarkers for Early Detection of SARS-CoV-2 Infection in Congregate Living Facilities | Incarcerated or Institutionalized Populations; Older Adults or Elderly | 800 | Screening Testing; Biosensor Technologies; At-Home or Over-the-Counter (OTC) Self-Testing | Longitudinal Cohort; Device Validation | Wearable; Chemosensory Testing Device; Antigen Testing Device | NIA; NIDCD | AFF-Four | No | |
| Cognitive and Neuroimaging Outcomes Following SARS-CoV-2 Infection in Older Adults with Pre-Existing Neurodegenerative Conditions | Older Adults or Elderly; Adults | 350 | Mental Health; Comorbidities; Long COVID | Longitudinal Cohort; Case-Control | Interview or Focus Group; Disease Registry | NINDS; NIA | AFF-One | No | |
| Complementary and Integrative Health Approaches for Managing Post-COVID Fatigue and Pain: A Randomized Pragmatic Trial | Rural Communities; Adults; Racial or Ethnic Minorities | 320 | Health Behaviors; Community Outreach Programs; Long COVID | Interventional or Clinical Trial | Survey; Wearable; Smartphone | NINR; NCCIH | Demo Affiliation 1 | No | |
| Contact Tracing Effectiveness and Network Analysis of SARS-CoV-2 Transmission in Tribal Nations | Racial or Ethnic Minorities; Underserved or Vulnerable Populations; Rural Communities | 4000 | Contact Tracing; Community Outreach Programs; Testing Rate or Uptake; Disease Surveillance | Observational; Mixed Methods | Smartphone; Survey; Antigen Testing Device; Contact Tracing | NIMHD; NIAID | Demo Affiliation 1 | No | |
| Coordinated Data Harmonization and Cross-Study Metadata Standardization for the RADx-UP Research Network | N/A | 0 | Digital Health Applications; Multimodal Surveillance | Open Cohort | Real-World Data; Survey | NIH OD; NLM; NIH CC; NCATS | Demo Affiliation 1 | No | |
| Cross-Sectional Survey of Vaccine Hesitancy, Health Behaviors, and COVID-19 Testing Uptake in Rural Appalachian Communities | Older Adults or Elderly; Lower Socioeconomic Status (SES) Populations; Rural Communities | 1500 | Community Outreach Programs; Testing Rate or Uptake; Health Behaviors; Vaccination Rate or Uptake | Cross-Sectional; Mixed Methods | Survey; Smartphone | NINR; NICHD | Demo Affiliation 1 | No | |
| Dental and Oral Health Impacts of SARS-CoV-2 Infection: Salivary Diagnostics, Oral Microbiome, and Periodontal Outcomes | Lower Socioeconomic Status (SES) Populations; Adults; Immigrants | 700 | Long COVID; Novel Biosensing or VOC; Diagnostic Testing | Case-Control; Longitudinal Cohort | Biobank Samples; Chemosensory Testing Device; Survey | NIAID; NIDCR | AFF-Three | No | |
| Development and Field Evaluation of Electrochemical Biosensors for Multiplexed Respiratory Pathogen Detection | Pregnant or Nursing Women; Adults | 350 | Medical Device or Tool Development; Novel Biosensing or VOC; Biosensor Technologies; Point-of-Care (POC) Testing | Interventional or Clinical Trial; Device Verification | Breath Analysis or Airborne Detection Device; Electrochemical Testing Device | NIDCR; NIBIB | AFF-Four | No | |
| Dialysis Patient COVID-19 Registry: Infection Outcomes, Vaccine Responses, and Antiviral Pharmacokinetics | African Americans; Adults; Older Adults or Elderly; Dialysis Patients | 1800 | Vaccination Rate or Uptake; Comorbidities; Immune Responses | Longitudinal Cohort; Observational | Disease Registry; Molecular Nucleic Acid or PCR Testing Device; Antibody or Adaptive Immune Response Testing | NIAID; NIDDK | AFF-One | No | |
| Digital Contact Tracing and Exposure Notification: Privacy, Adoption, and Public Health Impact Across Diverse Communities | Racial or Ethnic Minorities; Adults; Lower Socioeconomic Status (SES) Populations | 3500 | Contact Tracing; Digital Health Applications; Pandemic Perceptions or Decision-Making | Mixed Methods; Cross-Sectional | Survey; Smartphone; Interview or Focus Group | NIMHD; NLM | AFF-Three | No | |
| EUA-Authorized Home Test Accuracy Under Real-World Conditions: A Nationwide Prospective Assessment | Older Adults or Elderly; Adults; Rural Communities; Lower Socioeconomic Status (SES) Populations | 15000 | Testing Rate or Uptake; At-Home or Over-the-Counter (OTC) Self-Testing; Screening Testing | Cross-Sectional; Observational | Antigen Testing Device; Survey; Smartphone | NIBIB; NIH OD | Demo Affiliation 1 | No | |
| Electrochemical and Colorimetric Lateral Flow Assay Development for Simultaneous COVID-19 and Influenza Detection | Essential Workers; Children; Adults | 1500 | Influenza; Biosensor Technologies; Diagnostic Testing; Medical Device or Tool Development | Device Validation; Device Verification | Electrochemical Testing Device; Antigen Testing Device | NIBIB; NIAID | AFF-Two | No | |
| Epigenomic and Metagenomic Profiling of the Respiratory Microbiome in SARS-CoV-2 Infected and Recovered Patients | Adults; People Living with HIV/AIDS | 600 | Immune Responses; Next Generation Sequencing (NGS); Long COVID | Case-Control; Observational | Molecular Nucleic Acid or PCR Testing Device; Biobank Samples | NIAID; NIEHS | AFF-Three | No | |
| Eye Health Surveillance and Ophthalmic Manifestations of SARS-CoV-2 in Pediatric and Adult Populations | Children; Hispanics or Latinos; Adults | 1800 | Disease Surveillance; Screening Testing; Comorbidities | Cross-Sectional; Observational | Disease Registry; Real-World Data; Interview or Focus Group | NEI; NICHD | AFF-Two | No | |
| Family History, Genetic Susceptibility, and Intergenerational Transmission Patterns of SARS-CoV-2 in Multi-Generational Households | Asians; Older Adults or Elderly; Children; Native Hawaiians or Other Pacific Islanders | 1500 | Variants; Screening Testing; Immune Responses | Longitudinal Cohort | Molecular Nucleic Acid or PCR Testing Device; Antigen Testing Device; Survey | NICHD; NIA; NHGRI | AFF-Three | Yes | |
| Genomic Characterization and Clinical Correlation of SARS-CoV-2 Variants Using Targeted and Whole Genome Sequencing | Immigrants; Racial or Ethnic Minorities | 1800 | Variants; Next Generation Sequencing (NGS); Virological Testing | Clinical Genetic Testing; Observational | Biobank Samples; Molecular Nucleic Acid or PCR Testing Device | NCI; NHGRI | AFF-Three | Yes | |
| Genotype-Phenotype Correlations in COVID-19 Severity: A Multi-Ancestry Genome-Wide Association Study | Hispanics or Latinos; Racial or Ethnic Minorities; Native Hawaiians or Other Pacific Islanders; Asians; African Americans | 52000 | Social Determinants of Health; Variants | Case-Control | Biobank Samples; Disease Registry; Real-World Data | NHGRI; NIGMS; NIMHD | Demo Affiliation 1 | No | |
| Gut Microbiome Disruption, Enteric SARS-CoV-2 Shedding, and Gastrointestinal Manifestations of COVID-19 | Hispanics or Latinos; Adults; Children | 750 | Long COVID; Disease Surveillance; Wastewater Surveillance | Longitudinal Cohort | Biobank Samples; Survey; Wastewater Sampling | NIDDK; NIAID; NIEHS | AFF-Two | No | |
| Impact of COVID-19 on Maternal-Fetal Outcomes: Placental Genomics and Neonatal Immune Development | African Americans; Pregnant or Nursing Women; Children | 800 | Immune Responses; Comorbidities; Next Generation Sequencing (NGS) | Longitudinal Cohort | Real-World Data; Disease Registry; Biobank Samples | NIAID; NICHD | AFF-Three | Yes | |
| Longitudinal Analysis of Sleep Quality and Cognitive Decline in Older Adults | Adults | Testing Rate or Uptake | Clinical Genetic Testing | Interview or Focus Group | NDA | Demo University 1 | Yes | ||
| Longitudinal Assessment of Post-Acute Sequelae of SARS-CoV-2 (Long COVID) and Mental Health Outcomes in Urban Populations | Lower Socioeconomic Status (SES) Populations; Adults | 6200 | Health Behaviors; Mental Health; Long COVID | Longitudinal Cohort; Observational | Survey; Interview or Focus Group | NIMH; NIAID | AFF-One | No | |
| Methylation Array Profiling of Epigenetic Changes Associated with Severe COVID-19 and ICU Survivorship | Adults; Older Adults or Elderly | 600 | Comorbidities; Immune Responses; Long COVID | Longitudinal Cohort; Case-Control | Biobank Samples; Disease Registry | NHLBI; NHGRI | AFF-One | No | |
| Microscopy-Guided Spatial Transcriptomics of SARS-CoV-2 Tropism in Post-Mortem Lung and Brain Tissue | Older Adults or Elderly; Adults | 120 | Immune Responses; Variants; Next Generation Sequencing (NGS) | Observational | Biobank Samples | NCI; NIGMS; NIAID | AFF-One | No | |
| Mitochondrial DNA Heteroplasmy and Bioenergetic Dysfunction in Post-COVID Chronic Fatigue | Women (non-pregnant); Adults | 300 | Next Generation Sequencing (NGS); Long COVID | Case-Control | Biobank Samples; Molecular Nucleic Acid or PCR Testing Device | NIGMS; NINDS | AFF-Three | Yes | |
| Mobile COVID-19 Testing Units: Access, Uptake, and Impact on Health Disparities in Testing Desert Communities | Immigrants; Rural Communities; Underserved or Vulnerable Populations; Lower Socioeconomic Status (SES) Populations | 4200 | Mobile Unit Testing; COVID Testing Deserts; Community Outreach Programs; Social Determinants of Health; Testing Rate or Uptake | Mixed Methods; Cross-Sectional | Smartphone; Survey; Antigen Testing Device | NINR; NIMHD | AFF-Two | No | |
| Multimodal Surveillance Integration: Combining Influenza and COVID-19 Sentinel Networks for Respiratory Pathogen Forecasting | N/A | 0 | Multimodal Surveillance; Wastewater Surveillance; Disease Surveillance; Influenza | Open Cohort; Time-Series | Molecular Nucleic Acid or PCR Testing Device; Wastewater Sampling; Disease Registry; Real-World Data | NIH OD; NIAID | AFF-Two | No | |
| Multisystem Inflammatory Syndrome in Adults (MIS-A): Clinical Characterization, Risk Factors, and Cardiac Outcomes | Hispanics or Latinos; Adults; African Americans | 400 | Multisystem Inflammatory Syndrome (MIS); Comorbidities; Immune Responses | Longitudinal Cohort; Case-Control | Biobank Samples; Interview or Focus Group; Disease Registry | NHLBI; NIAID | AFF-One | No | |
| Multisystem Inflammatory Syndrome in Children (MIS-C): Genomic Risk Factors and Longitudinal Immune Profiling | Children; African Americans; Hispanics or Latinos | 400 | Immune Responses; Multisystem Inflammatory Syndrome in Children (MIS-C); Next Generation Sequencing (NGS) | Case-Control; Longitudinal Cohort | Disease Registry; Biobank Samples | NHGRI; NICHD; NIAID | AFF-One | No | |
| Non-Human Primate Model of SARS-CoV-2 Reinfection: Genotypic and Phenotypic Determinants of Immune Escape | N/A | 48 | Virological Testing; Variants; Immune Responses | Interventional or Clinical Trial | Molecular Nucleic Acid or PCR Testing Device; Biobank Samples | NIAID; NIGMS | AFF-Four | No | |
| Pandemic Perceptions, Misinformation Exposure, and Decision-Making Among Pregnant and Nursing Women During COVID-19 | Pregnant or Nursing Women; Racial or Ethnic Minorities; Native Hawaiians or Other Pacific Islanders | 1200 | Vaccination Rate or Uptake; Mental Health; Pandemic Perceptions or Decision-Making | Mixed Methods; Cross-Sectional | Survey; Interview or Focus Group; Smartphone | NICHD; NIMH | Demo Affiliation 1 | No | |
| Physical Activity, Wearable-Derived Biomarkers, and COVID-19 Recovery Trajectories Among College Athletes | Adults; School Communities | 650 | Long COVID; Biosensor Technologies; Health Behaviors | Longitudinal Cohort; Observational | Wearable; Survey; Real-World Data | NIAMS; NHLBI | AFF-Two | No | |
| Proteomic and Metabolomic Signatures of Severe COVID-19 in Patients with Substance Use Disorders | Adults; Homeless or Unhoused Populations; Sexual or Gender Minorities | 300 | Substance Use; Comorbidities; Immune Responses | Observational; Case-Control | Disease Registry; Biobank Samples; Real-World Data | NIDA; NIAAA; NIGMS | AFF-One | No | |
| Randomized Controlled Trial of a Digital Health Intervention for COVID-19 Self-Management and Remote Monitoring | Native Hawaiians or Other Pacific Islanders; Asians; Adults | 400 | Biosensor Technologies; Disease Surveillance; Digital Health Applications | Interventional or Clinical Trial | Smartphone; Wearable; Survey | NHLBI; NLM | AFF-Three | Yes | |
| Rapid Assessment of SARS-CoV-2 Variant Surveillance Using Next-Generation Point-of-Care Diagnostics in Underserved Communities | Underserved or Vulnerable Populations; Racial or Ethnic Minorities | 3500 | Diagnostic Testing; Point-of-Care (POC) Testing; Disease Surveillance | Observational; Cross-Sectional | Molecular Nucleic Acid or PCR Testing Device; Antigen Testing Device | NIAID; NIBIB | AFF-Three | Yes | |
| Rapid Diagnostic Test Performance Across SARS-CoV-2 Variants: A Multi-Platform Comparative Verification Study | Essential Workers; Adults; Pregnant or Nursing Women | 4500 | Diagnostic Testing; Variants; Serological or Antibody Testing; Rapid Diagnostic Test (RDT) | Device Verification; Cross-Sectional | Molecular Nucleic Acid or PCR Testing Device; Antigen Testing Device; Antibody or Adaptive Immune Response Testing; Unspecified COVID Testing Device | NIBIB; NCATS | AFF-Four | No | |
| Real-Time Breath Analysis for Non-Invasive SARS-CoV-2 Detection in Emergency Department Triage Settings | Adults; Older Adults or Elderly | 1800 | Point-of-Care (POC) Testing; Novel Biosensing or VOC; Screening Testing | Device Validation; Cross-Sectional | Molecular Nucleic Acid or PCR Testing Device; Breath Analysis or Airborne Detection Device | NIBIB; NHLBI | AFF-Two | No | |
| SNP Array-Based Pharmacogenomic Profiling to Optimize COVID-19 Treatment Responses Across Diverse Populations | Adults; Hispanics or Latinos; Racial or Ethnic Minorities; African Americans | 12000 | Variants; Artificial Intelligence or Machine Learning; Social Determinants of Health | Observational; Case-Control | Real-World Data; Disease Registry; Biobank Samples | NCATS; NIGMS; NIMHD | AFF-Four | No | |
| Sanger Sequencing-Based Confirmation of SARS-CoV-2 Mutations in Resource-Limited Clinical Laboratories | N/A | 600 | Diagnostic Testing; Virological Testing; Variants | Observational; Cross-Sectional | Biobank Samples; Molecular Nucleic Acid or PCR Testing Device | NIAID; NLM | AFF-Three | Yes | |
| Seroprevalence and Durability of Hybrid Immunity in Healthcare Workers Following Sequential Vaccination and Breakthrough Infection | Essential Workers; Adults | 1500 | Vaccination Rate or Uptake; Immune Responses; Seroprevalence | Longitudinal Cohort | Antibody or Adaptive Immune Response Testing; Real-World Data; Survey | NHLBI; NIAID | AFF-One | No | |
| Single-Cell Multi-Omics Atlas of Immune Dysregulation in Severe Pediatric COVID-19 and MIS-C | Hispanics or Latinos; Racial or Ethnic Minorities; Children | 350 | Next Generation Sequencing (NGS); Immune Responses; Multisystem Inflammatory Syndrome in Children (MIS-C) | Case-Control | Disease Registry; Biobank Samples | NIAID; NHGRI; NICHD | AFF-Four | No | |
| Social Determinants of Health and COVID-19 Comorbidity Burden Among Homeless and Incarcerated Populations | Incarcerated or Institutionalized Populations; Homeless or Unhoused Populations; Underserved or Vulnerable Populations; Sexual or Gender Minorities | 800 | Social Determinants of Health; Comorbidities; Substance Use; COVID Testing Deserts | Cross-Sectional; Mixed Methods | Interview or Focus Group; Disease Registry; Real-World Data | NIDA; NIMHD | Demo Affiliation 1 | No | |
| Somatic Variant Analysis and Tumor Microenvironment Characterization in Cancer Patients with Concurrent SARS-CoV-2 Infection | Intellectual or Developmental Disabilities; Adults; Asians | 200 | Immune Responses; Variants; Comorbidities | Clinical Genetic Testing; Case-Control | Biobank Samples; Molecular Nucleic Acid or PCR Testing Device; Antibody or Adaptive Immune Response Testing | NCI; NIAMS | Demo Affiliation 1 | No | |
| Supporting Documents Repository and Standardized Protocol Library for RADx COVID-19 Testing Research Network | N/A | 0 | Screening Testing; Medical Device or Tool Development; Multimodal Surveillance | Open Cohort | Survey; Real-World Data | NIH OD; NIH CC; NLM | Demo Affiliation 1 | No |